Scientists have discovered a new biomarker to identify which patients with brain tumors called glioblastomas -- the most common and malignant of primary brain tumors -- might benefit from immunotherapy. The treatment could extend survival for an estimated 20% to 30% of patients. Currently, patients with glioblastoma do not receive this life-prolonging treatment because it has not been fully understood which of them could benefit.
from Latest Science News -- ScienceDaily https://www.sciencedaily.com/releases/2021/11/211129155034.htm
from Latest Science News -- ScienceDaily https://www.sciencedaily.com/releases/2021/11/211129155034.htm
Which glioblastoma patients will respond to immunotherapy?
![Which glioblastoma patients will respond to immunotherapy?]()
Reviewed by cmakigo
on
December 01, 2021
Rating:
No comments:
Post a Comment